New drugs for hepatitis C virus (HCV)

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 14, Issue 2, 2000, Pages 293-305

  Clarke, Berwyn E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anti viral; Hepatitis C virus; Immunomodulation; interferon

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; REVIEW; SIDE EFFECT; VIRUS REPLICATION;

EID: 0034086445     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.1999.0077     Document Type: Article

References (61)

1. Alter M J. Epidemiology of hepatitis C. Hepatology. 26:1997;62-65.
2. Seeff L B, Buskell-Bales Z, Wright E C. Long-term mortality after transfusion-associated non-A non-B hepatitis. New England Journal of Medicine. 72:1992;1906-1911.
3. Darby S C, Ewart D W, Giangrande P LF. Mortality from liver cancer and liver disease in haemophiliac men and boys given blood products contaminated with hepatitis C. Lancet. 349:1997;1425-1431.
4. El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine. 340:1999;745-750.
5. McHutchison J G, Gordon S C, Schiff E R. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine. 339:1998;1485-1492.
6. Poynard T, Marcellin P, Lee S. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
7. Davis G L, Esteban-Mur R, Rustgi V. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine. 339:1998;1493-1499.
8. Davis G L, Balart L A, Schiff E R. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicentre randomized, controlled trial. New England Journal of Medicine. 321:1989;1501-1506.
9. Di Bisceglie A M, Martin P, Kassianides C. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double blind placebo-controlled trial. New England Journal of Medicine. 321:1989;1506-1510.
10. Marcellin P, Boyer N, Giostra E. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicentre randomized controlled trial from France. Hepatology. 13:1991;393-397.
11. Causse X, Godinot H, Chevallier M. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
12. Poynard T, Bedossa P, Chevallier M. A comparison of three interferon alfa-2B regimens for the long-term treatment of chronic non-A, non-B hepatitis. New England Journal of Medicine. 332:1995;1457-1462.
13. Fried M W, Shiffmann M L, Sterling R K. A multicenter, randomized trial of daily high dose interferon alfa-2b for the treatment of chronic hepatitis C: prospective stratification by viral burden and genotype. Gastroenterology. 114:1998;A1242.
14. Ouzan D, Babany G, Valla D, Opolon P. Comparison of high initial and fixed-dose regimens of interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial. Journal of Viral Hepatitis. 5:1998;53-59.
15. Bosch O, Tapia L, Quiroga J A, Carreno V. An escalating dose regime of recombinant interferon alpha-2a in the treatment of chronic hepatitis C. Journal of Hepatology. 17:1993;146-149.
16. Shiffmann M L, Hofmann C M, Luketic V A, Thompson E B, Sanyal A J. Treatment of chronic hepatitis C with escalating doses of interferon alpha-2b increases both biochemical and virologic response. Hepatology. 22:1995;152A.
17. Shiffman M L. Use of high-dose interferon in the treatment of chronic hepatitis C. Seminars in Liver Disease. 19:1999;25-34.
18. Tong M J, Reddy K R, Lee W M. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology. 26:1997;747-754.
19. Foster G R, Finter N B. Are all type 1 interferons equivalent? Journal of Viral Hepatitis. 5:1998;143-152.
20. Meister A, Uze G, Mogensen K E. Biological activities and receptor binding of two human recombinant interferons and their hybrids. Journal of General Virology. 67:1986;1633-1643.
21. Xu Z -X, Hoffmann J, Patel I. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects. Hepatology. 28:1998;702A.
22. Bodenheimer H C, Lindsay K L, Davis G L. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 26:1997;473-477.
23. Reichard O, Norkrans G, Fryden A. Randomised double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:1998;83-86.
24. Chemello L, Cavalletto L, Bernardinello E. The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. Journal of Hepatology. 23:1995;8-12.
25. Lai M Y, Kao J H, Yang P M. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 111:1996;1307-1312.
26. McHutchison J G, Gordon S C, Schiff E R. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine. 339:1998;1485-1492.
27. Poynard T, Marcellin P, Lee S. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
28. Davis G L, Esteban-Mur R, Rustgi V. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine. 339:1998;1493-1499.
29. Maddrey W C. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis-C relapsed and treatment-naïve patients. Seminars in Liver Disease. 19:1999;67-75.
30. Smith J P. Treatment of chronic hepatitis C with amantadine. Digestive Diseases and Sciences. 42:1997;1681-1687.
31. Khalili M, Olmeda M, Yantsos V. Pilot study of intron-A and ribavirin vs intron-A and amantadine in interferon non-responders with chronic hepatitis C. Gastroenterology. 114:1998;1271.
32. Brillanti S, Foli M, Gramantieri L. Triple antiviral therapy for chronic hepatitis C in interferon alfa non-responders: a pilot randomized controlled study. Hepatology. 26:1997;367A.
33. Younossi Z M, Perrillo R P. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Seminars in Liver Disease. 19:1999;95-102.
34. Davis G L, Nelson D R, Reyes G R. Future options for the management of hepatitis C. Seminars in Liver Disease. 19:1999;103-112.
35. Choo Q L, Richman K H, Han J H. Genetic organisation and diversity of the hepatitis C virus. Proceedings of the National Academy of Sciences of the USA. 88:1991;2451-2455.
36. Clarke B E. Molecular virology of hepatitis C virus. Journal of General Virology. 78:1997;2397-2410.
37. Zitzmann N, Mehta A S, Carrouee S. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proceedings of the National Academy of Sciences of the USA. 96:1999;11878-11882.
38. Sizova D V, Kolupaeva V G, Pestova T V. Specific interaction of eukaryotic translation initiation factor 3 with the 5′ nontranslated regions of hepatitis C virus and classical swine fever virus. Journal of Virology. 72:1998;4775-4782.
39. Pestova T V, Shatsky I N, Fletcher S P. A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes and Development. 12:1998;67-83.
40. Brown-Driver V, Eto T, Lesnik E. Inhibition of translation of hepatitis C virus RNA by 2′-modified antisense oligonucleotides. Antisense and Nucleic Acid Drug Development. 9:1999;145-154.
41. Lieber A, He C -Y, Polyak S. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. Journal of Virology. 70:1996;8782-8791.
42. Tanaka T, Kato N, Cho M J, Shimotohno K. A novel sequence found at the 3′ terminus of the hepatitis C virus genome. Biochemical and Biophysical Research Communications. 215:1995;744-749.
43. Kolykhalov A A, Agapov E V, Blight K J. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 277:1997;570-574.
44. Grakoui A, Wychowski C, Lin C. Expression and identification of hepatitis C virus polyprotein cleavage products. Journal of Virology. 67:1993;1385-1395.
45. Shoji I, Suzuki T, Sato M. Internal processing of hepatitis C virus NS3 protein. Virology. 254:1999;315-323.
46. Bartenschlager R, Lohmann V, Wilkinson T. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. Journal of Virology. 69:1995;7519-7528.
47. Kakiuchi N, Nishikawa S, Hattori M. A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. Journal of Virological Methods. 80:1999;77-84.
48. Cicero D O, Barbato G, Koch U. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling. Journal of Molecular Biology. 289:1999;385-396.
49. Kim J L, Morgenstern K A, Lin C. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 87:1996;343-355.
50. LaPlante S R, Cameron D R, Aubry N. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. Journal of Biological Chemistry. 274:1999;18618-18624.
51. Preugschat F, Averett D R, Clarke B E, Porter D JT. A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. Journal of Biological Chemistry. 271:1996;24449-24457.
52. Yao N, Hesson T, Cable M. Structure of the hepatitis C virus RNA helicase domain. Nature Structural Biology. 4:1997;463-467.
53. Morgenstern K A, Landro J A, Hsiao K. Polynucleotide modulation of the protease, nucleoside triphosphatase and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells. Journal of Virology. 71:1997;3767-3775.
54. Oh J -W, Ito T, Lai M MC. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA. Journal of Virology. 73:1999;7694-7702.
55. Lesburg C A, Cable M B, Ferrari E. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Structural Biology. 6:1999;937-943.
56. Major M E, Mihalik K, Fernandez J. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. Journal of Virology. 73:1999;3317-3325.
57. Yanagi M, St Claire M, Shapiro M. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology. 244:1998;161-172.
58. Beard M R, Abell G, Honda M. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology. 30:1999;316-324.
59. Lohmann V, Korner F, Koch J. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285:1999;110-113.
60. Feray C, Gigou M, Samuel D. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Annals of Internal Medicine. 128:1998;810-816.
61. Koziel M. The role of immune responses in the pathogenesis of hepatitis C virus infection. Journal of Viral Hepatitis. 4S1:1997;31-41.